Shionogi, Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 300
- Registration Number
- NCT03032380
- Locations
- 🇺🇦
Shionogi Research Site, Zaporizhzhya, Ukraine
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 1436
- Registration Number
- NCT02954354
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 2184
- Registration Number
- NCT02949011
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 152
- Registration Number
- NCT02714595
- Locations
- 🇬🇧
Shionogi Research Site, London, England, United Kingdom
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 631
- Registration Number
- NCT02638337
Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 215
- Registration Number
- NCT02389621
A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 452
- Registration Number
- NCT02321800
Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 553
- Registration Number
- NCT01993940
- Locations
- 🇺🇸
Shionogi Research Site, Clarksburg, West Virginia, United States
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 547
- Registration Number
- NCT01965158
- Locations
- 🇬🇧
Shionogi Research Site, Tomairt, United Kingdom
Long Term Safety of Naldemedine
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 1246
- Registration Number
- NCT01965652
- Locations
- 🇬🇧
Shionogi Research Site, York, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath